Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Invested Capital (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Invested Capital for 15 consecutive years, with $1.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital fell 24.37% year-over-year to $1.1 billion; the TTM value through Mar 2026 reached $1.1 billion, down 24.37%, while the annual FY2025 figure was $1.2 billion, 22.57% down from the prior year.
  • Invested Capital hit $1.1 billion in Q1 2026 for Agios Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $1.6 billion in Q3 2024 and bottomed at $660.5 million in Q2 2024.
  • Average Invested Capital over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2026.
  • Year-over-year, Invested Capital tumbled 47.43% in 2022 and then surged 107.35% in 2025.
  • Agios Pharmaceuticals' Invested Capital stood at $1.1 billion in 2022, then dropped by 26.33% to $811.0 million in 2023, then soared by 90.0% to $1.5 billion in 2024, then dropped by 22.57% to $1.2 billion in 2025, then fell by 7.04% to $1.1 billion in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $1.1 billion, $1.2 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.